Association of prior immune checkpoint blockade (ICB) with longer progression-free survival (PFS) in patients treated with intermittent versus continuous dabrafenib and trametinib: A post-hoc analysis of S1320.

Alain Patrick Algazi,Megan Othus,Adil Daud,Janice M. Mehnert,Thach-Giao Truong,Robert M. Conry,Kari Kendra,Gary C. Doolittle,Joseph I. Clark,Michael J. Messino,Dennis F. Moore,Christopher D. Lao,Bryan A. Faller,Rangaswamy Govindarajan,Amy K. Harker-Murray,Luke Dreisbach,James C. Moon,Kenneth F. Grossmann,Roger S. Lo,Antoni Ribas

Association of prior immune checkpoint blockade (ICB) with longer progression-free survival (PFS) in patients treated with intermittent versus continuous dabrafenib and trametinib: A post-hoc analysis of S1320.

2020

10039Background: S1320 is a phase 2 randomized clinical trial presented at the 2020 AACR Annual Meeting in April demonstrating that continuous dosing of dabrafenib and trametinib yields longer PFS ...

Keywords:

Blockade
Oncology
Internal medicine
Progression-free survival
Post-hoc analysis
Trametinib
Dabrafenib
in patient
Pathology
Immune checkpoint
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations